AIM ImmunoTech Inc. vs. Repligen Corp
AIM ImmunoTech Inc. (AIM) comes out ahead, leading on 2 of 3 compared factors.
Size & Scale
| AIM | RGEN | |
|---|---|---|
| Market Cap | $6.69 million | $9.42 billion |
| Revenue (TTM) | — | $785.10 million |
| Net Income (TTM) | — | $41.54 million |
RGEN leads on 1 of 1 size & scale factors.
Valuation
| AIM | RGEN | |
|---|---|---|
| P/E Ratio | — | 229.55 |
| Price / Book | 0.57 | 4.46 |
| Price / Sales | — | 11.99 |
AIM leads on 1 of 1 valuation factors.
Profitability
| AIM | RGEN | |
|---|---|---|
| Net Margin | — | 5.29% |
| Return on Equity | — | 1.97% |
AIM and RGEN split the profitability factors evenly.
Risk & Sentiment
| AIM | RGEN | |
|---|---|---|
| Short Interest | 0.32% | 7.13% |
AIM leads on 1 of 1 risk & sentiment factors.
Dig deeper: AIM overview, AIM financials, RGEN overview, RGEN financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.